Population pharmacokinetic modeling and pharmacodynamic assessment of cefozopran in pediatric patients

Japanese Journal of Antibiotics

Volumn 62, Issue 5, 2009, Pages 435-444

  Ikawa, Kazuro ^a   Kozumi, Toshihiro ^a   Ikeda, Kayo ^a   Morikawa, Norifumi ^a   Kobayashi, Ryoji ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b SAPPORO HOKUYU HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFOZOPRAN; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM; BIOLOGICAL MODEL; CHILD; DRUG ADMINISTRATION; DRUG EFFECT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGICAL EXAMINATION; MONTE CARLO METHOD;

ANTI-BACTERIAL AGENTS; BACTERIA; CEPHALOSPORINS; CHILD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HUMANS; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD;

EID: 77649224736     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. OOKUBO, H.: Outline of the drug use result survey of Firstcin (cefozopran hydrochloride) as part of postmarketing surveillance in Japan. Jpn. J. Antibiotics 58:469-485, 2005
2. IKAWA, K.; K. NOMURA, N. MORIKAWA, et al: Pharmacokinetic-pharmacodynamic target attainment analysis of cefozopran in Japanese adult patients. J. Infect. Chemother. 14: 130 - 136, 2008 (Pubitemid 351624466)
3. CRAIG, W. A.: Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22: 89-96, 1995
4. MOUTON, J. W; M. N. DUDLEY, O. CARS, et al: Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55: 601-607, 2005 (Pubitemid 40691835)
5. IKAWA, K.; N. MORIKAWA, S. HAYATO, et al: Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients. Int. J. Antimicrob. Agents 30: 270-273, 2007 (Pubitemid 47126816)
6. IKAWA, K.; N. MORIKAWA, K. FUKUHARA, et al: Penetration and exposure of cefotiam into the peritoneal fluid of abdominal surgery patients after intravenous administration. J. Chemother. 20: 319-323, 2008 (Pubitemid 351998892)
7. SATO, T.; R. KOBAYASHI, K. YASUDA, et al: A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. Pediatr. Blood Cancer 51: 774-777, 2008
8. FUJII, R.; K. SUNAKAWA, Y. SATO, et al: Optimum dose study of cefozopran in the pediatric field. Jpn. J. Antibiotics 49: 663-677, 1996 (Pubitemid 26264978)
9. IKEDA, K.; N. MORIKAWA, M. KURIBAYASHI, et al: Real-time therapeutic drug monitoring of cefozopran in plasma using high-performance liquid chromatography with ultraviolet detection. J. Pharm. Biomed. Anal. 45: 811-816, 2007 (Pubitemid 350087558)
10. TAKEDA, M. & K. MAEDA: Microbiological assay method for cefozopran in biological specimens. Jpn. J. Chemother. 41(Suppl. 4): 135-141, 1993 (Pubitemid 24059665)
11. YAMAGUCHI, K.; Y. ISHII, M. IWATA, et al: Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004. Jpn. J. Antibiotics 58: 655-689, 2005 (Pubitemid 43151930)
12. KONDO, T.; K. YOSHIDA & S. TANAYAMA: Metabolic fate of cefozopran hydrochloride, a new broad-spectrum cephalosporin, in rats and dogs. Jpn. J. Chemother. 41(Suppl. 4): 81-95, 1993 (Pubitemid 24059659)
13. BURGESS, D. S. & C. R. FREI: Comparison of beta-lactam regimens for the treatment of Gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J. Antimicrob. Chemother. 56: 893-898, 2005 (Pubitemid 41631914)
14. SAKURAI, Y.; T. HISHIKAWA, N. HIRAMATSU, et al: Pharmacokinetic analysis of cefozopran in neonatal infections - population pharmacokinetics using NONMEM. Jpn. J. Antibiotics 52: 16-23, 1999 (Pubitemid 29078991)